Mycenax Biotech Inc. (4726.TWO)
TWD 31.15
(1.14%)
TWD 31.15
(1.14%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 652.62 Million | 732.27 Million | 774.27 Million | 665.34 Million | 390.84 Million |
| Cost of Revenue | 1.02 Billion | 845.94 Million | 636.66 Million | 478.8 Million | 258.33 Million |
| Gross Profit | -375.19 Million | -113.67 Million | 137.6 Million | 186.53 Million | 132.5 Million |
| Operating Expenses | -375.19 Million | 300.16 Million | 230.09 Million | 140.26 Million | 362.76 Million |
| Selling, General and Administrative Expenses | 152.22 Million | 156.16 Million | 133.96 Million | 93.76 Million | 78.19 Million |
| Research and Development Expenses | 75.81 Million | 144 Million | 96.13 Million | 46.5 Million | 284.56 Million |
| Other Expenses | - | -14.98 Million | 1.38 Million | 1.16 Million | - |
| Cost and Expenses | 1.25 Billion | 1.14 Billion | 866.75 Million | 619.07 Million | 621.09 Million |
| Operating Income | -602.1 Million | -412.48 Million | -92.14 Million | 39.69 Million | -230.25 Million |
| Interest Expense | 27.24 Million | 19.19 Million | 2.53 Million | 865 Thousand | 1.92 Million |
| Income Tax Expense | -1.13 Million | -9.21 Million | 2.34 Million | -2.98 Million | 11.79 Million |
| Earnings before Tax | -683.98 Million | -462.84 Million | -87.51 Million | 27.96 Million | -229.97 Million |
| Net Income | -682.84 Million | -453.63 Million | -89.85 Million | 30.94 Million | -218.17 Million |
| Earnings Per Share Basic | -3.32 | -2.74 | -0.61 | 0.24 | -1.74 |
| Earnings Per Share Diluted | -3.32 | -2.74 | -0.61 | 0.24 | -1.74 |
| Weighted Average Shares Outstanding | 205.52 Million | 165.33 Million | 148.48 Million | 127.99 Million | 125.38 Million |
| Weighted Average Shares Outstanding (Diluted) | 205.52 Million | 165.33 Million | 148.48 Million | 128.71 Million | 125.73 Million |
| Gross Margin | -0.57 | -0.16 | 0.18 | 0.28 | 0.34 |
| EBIT Margin | -0.52 | -0.18 | 0.10 | 0.27 | -0.32 |
| Profit Margin | -1.05 | -0.62 | -0.12 | 0.05 | -0.56 |
| EBITDA | -339.48 Million | -160.33 Million | 82.83 Million | 176.89 Million | -104.76 Million |
| Earnings Before Tax Margin | -0.92 | -0.56 | -0.12 | 0.06 | -0.59 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 200.61 Million | 80.19 Million | 182.91 Million | 652.62 Million | 113.26 Million | 218.04 Million |
| Cost of Revenue | 251.14 Million | 166.88 Million | 260.05 Million | 1.02 Billion | 214.99 Million | 310.16 Million |
| Gross Profit | -50.53 Million | -86.69 Million | -77.13 Million | -375.19 Million | -101.73 Million | -92.11 Million |
| Operating Expenses | 56.06 Million | 49.9 Million | 47.49 Million | 228.04 Million | 57.89 Million | 61.19 Million |
| Selling, General and Administrative Expenses | 37.31 Million | 35.99 Million | 31.63 Million | - | 39.32 Million | 42.08 Million |
| Research and Development Expenses | 18.75 Million | 13.9 Million | 15.85 Million | - | 18.57 Million | 19.11 Million |
| Other Expenses | 11.1 Million | 292 Thousand | 2.74 Million | -66.93 Million | 1.61 Million | 6.82 Million |
| Cost and Expenses | 307.2 Million | 216.79 Million | 307.54 Million | 1.25 Billion | 272.89 Million | 371.36 Million |
| Operating Income | -92.07 Million | -127.75 Million | -143.89 Million | -657.86 Million | -135.88 Million | -135.73 Million |
| Interest Expense | 8.32 Million | 6.14 Million | 6.51 Million | 27.24 Million | 6.74 Million | 6.86 Million |
| Income Tax Expense | 63 Thousand | 2.5 Million | 3.77 Million | -1.13 Million | 1.21 Million | 1.09 Million |
| Earnings before Tax | -101.55 Million | -133.1 Million | -148.72 Million | -683.98 Million | -120.78 Million | -166.29 Million |
| Net Income | -101.61 Million | -135.61 Million | -152.49 Million | -682.84 Million | -121.99 Million | -167.39 Million |
| Earnings Per Share Basic | -0.49 | -0.66 | -0.74 | - | -0.59 | -0.82 |
| Earnings Per Share Diluted | -0.49 | -0.66 | -0.74 | - | -0.59 | -0.82 |
| Weighted Average Shares Outstanding | 207.37 Million | 205.47 Million | 206.15 Million | 205.52 Million | 206.77 Million | 204.13 Million |
| Weighted Average Shares Outstanding (Diluted) | 207.37 Million | 205.47 Million | 206.15 Million | 205.52 Million | 206.77 Million | 204.13 Million |
| Gross Margin | -0.25 | -1.08 | -0.42 | -0.57 | -0.90 | -0.42 |
| EBIT Margin | -0.08 | -0.63 | -0.36 | - | -0.52 | -0.26 |
| Profit Margin | -0.51 | -1.69 | -0.83 | -1.05 | -1.08 | -0.77 |
| EBITDA | -15.41 Million | -50.4 Million | -66.02 Million | - | -58.4 Million | -57.37 Million |
| Earnings Before Tax Margin | -0.46 | -1.59 | -0.79 | -1.01 | -1.20 | -0.62 |
XLEFF
KSS
BMCLF
9265
MAQCW
MEDANTA